Invega Sustenna Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Alerts
• Clinical Trials
• Forums

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
Condition:   Schizophrenia Interventions:   Drug: Risperidone 3 mg;   Drug: Paliperidone Palmitate 50 mg eq.;   Drug: Paliperidone Palmitate 75 mg eq.;   Drug: Paliperidone Palmitate 100 mg eq.;   Drug: Paliperidone Palmitate 150 mg eq.;   Drug: Paliperidone Palmitate 175 mg eq.;   Drug: Paliperidone Pa lmitate 263 mg eq.;   Drug: Paliperidone Palmitate 350 mg eq.;   Drug: Paliperidone Palmitate 525 mg eq. Sponsor:   Janssen-Cilag International NV Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 25, 2021 Category: Research Source Type: clinical trials

Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment
Condition:   Schizophrenics Interventions:   Drug: Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega];   Drug: Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA] Sponsor:   Calo Psychiatric Center Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2021 Category: Research Source Type: clinical trials